Iron deficiency remains the most common nutrient deficiency worldwide, yet many patients fail to achieve optimal iron status despite supplementation and dietary interventions. In refractory cases, the limitation is often not iron intake alone, but the gastrointestinal (GI) microbiome environment that governs absorption, utilization, and storage.
Serum iron reflects circulating iron at a single point in time and is subject to diurnal variation, whereas ferritin is the most widely used biomarker of total body iron stores and the most reliable laboratory indicator of iron deficiency in the absence of inflammation. Because ferritin is an acute-phase reactant, interpretation should always consider inflammatory status, commonly assessed with hs-CRP, ESR, and fecal calprotectin when GI inflammation is suspected. When ferritin remains low alongside symptoms such as fatigue, hair loss, restless legs syndrome, brain fog, or reduced exercise tolerance, clinicians should evaluate beyond dietary intake alone.
Emerging evidence highlights a gut–microbiome–inflammation axis influencing iron homeostasis through mucosal immune activity, short-chain fatty acid production, intestinal barrier integrity, and hepcidin signaling.
Hepcidin: The Master Regulator
Iron absorption is tightly regulated by hepcidin, a liver-derived peptide hormone that controls systemic iron availability. Inflammatory cytokines, particularly interleukin-6 (IL-6), increase hepcidin synthesis, reducing intestinal iron absorption and promoting iron sequestration in storage sites. The result is functional iron deficiency despite adequate intake or supplementation. Chronic low-grade inflammation, whether systemic or localized within the GI tract, can therefore limit iron availability and contribute to refractory iron deficiency.
The Bidirectional Gut–Iron Relationship
The gut microbiome plays a central role in iron regulation. Human studies associate iron deficiency with reduced microbial diversity, altered microbial composition, impaired intestinal barrier function, and disrupted host–microbe interactions. Conversely, dysbiosis and intestinal inflammation may further impair iron absorption through epithelial dysfunction and altered regulatory signaling. Patients with dysbiosis frequently demonstrate reduced abundance of butyrate-producing organisms. Butyrate serves as the primary energy source for colonocytes, supports tight junction integrity, and promotes anti-inflammatory signaling. Reduced butyrate production may therefore contribute to impaired nutrient absorption and immune dysregulation, helping explain persistently low ferritin despite appropriate supplementation.
Practical Clinical Application: Targeted Testing
In patients with unexplained or treatment-resistant low ferritin, comprehensive stool testing with the GI360™ profile may provide clinically relevant insight into potential gastrointestinal contributors to impaired iron homeostasis. Findings commonly associated with altered iron availability and absorption include:
-
Evidence of mucosal immune activation (e.g., elevated fecal calprotectin and/or secretory IgA)
-
Reduced short-chain fatty acid production, particularly butyrate
-
Low microbial Diversity Score
-
Elevated Dysbiosis Index
In patients with persistent iron deficiency where GI microbiome findings do not fully account for low ferritin, integration of GI360™ results with a DDI Urine Toxic Elements Profile may provide additional context. Iron deficiency is associated with upregulation of intestinal Divalent Metal Transporter 1 (DMT1), a compensatory mechanism that enhances non-heme iron absorption, but may also increase intestinal uptake of other divalent metals, including cadmium and, to a lesser extent, lead, particularly in the setting of altered gut barrier function.
Incretin-Based Therapies
Patients with reduced food intake, including those receiving GLP-1 receptor agonists or incretin therapy (dual GIP/GLP-1 receptor agonists), present an additional consideration. These therapies slow gastric emptying, reduce appetite, and often decrease overall caloric and dietary iron intake. They may also alter GI motility and the intestinal microbial environment, potentially contributing to dysbiosis or intestinal inflammation. In patients presenting with declining ferritin, fatigue, or constipation, stool testing may help differentiate reduced dietary iron intake, altered GI physiology, inflammation, and dysbiosis.
Clinical Takeaway
Iron deficiency is increasingly recognized as a multifactorial condition reflecting immune activation, microbial imbalance, and GI dysfunction. Addressing these underlying mechanisms allows clinicians to move beyond iron repletion alone toward more precise, individualized strategies that support long-term restoration of iron balance and patient health.
